公开(公告)号：US06773908B1

公开(公告)日：2004-08-10

申请号：US09601326

申请日：2000-09-25

Applicant: Prem S. Paul ,  Yanjin Zhang

Inventor： Prem S. Paul ,  Yanjin Zhang

IPC: C12N700

CPC classification number: A61K39/12 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/51 ,  A61K2039/5254 ,  A61K2039/552 ,  C07K14/005 ,  C12N7/00 ,  C12N2770/10021 ,  C12N2770/10022 ,  C12N2770/10034 ,  C12N2770/10064 ,  G01N33/56983

Abstract: The present invention provides an isolated DNA sequence encoding, for example, at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), specifically ISU-55, and the polypeptides encoded by the isolated DNA sequences. The present invention also concerns a vaccine comprising an effective amount of such a protein; methods of producing antibodies which specifically bind to such a protein; and methods of protecting a pig against a PRRSV, and treating a pig infected by a PRRSV.

Abstract translation: 本发明提供了一种分离的DNA序列，其编码例如至少一种选自由爱滋病猪繁殖与呼吸综合征病毒（PRRSV）的一个或多个开放阅读框（ORF's）编码的蛋白质的多肽， 特别是ISU-55，以及由分离的DNA序列编码的多肽。 本发明还涉及包含有效量的这种蛋白质的疫苗; 产生特异性结合这种蛋白质的抗体的方法; 以及保护猪免于PRRSV的方法，以及治疗由PRRSV感染的猪。

公开(公告)号：US06764845B2

公开(公告)日：2004-07-20

申请号：US10340389

申请日：2003-01-10

Applicant: Hema S. Sista ,  Yero J. Espinoza

Inventor： Hema S. Sista ,  Yero J. Espinoza

IPC: C12N700

CPC classification number: A61K47/26 ,  A61K9/0019 ,  A61K38/4846 ,  A61K47/10 ,  A61K48/00 ,  A61K48/0008 ,  A61K48/0091 ,  C12N15/86 ,  C12N2750/14143 ,  C12N2750/14151

Abstract: Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions.

公开(公告)号：US06656719B1

公开(公告)日：2003-12-02

申请号：US09176492

申请日：1998-10-21

Applicant: Sandra L. Gould ,  David K. Robinson ,  Daniel J. Distefano ,  T. Craig Seamans

Inventor： Sandra L. Gould ,  David K. Robinson ,  Daniel J. Distefano ,  T. Craig Seamans

IPC: C12N700

CPC classification number: A61K39/15 ,  A61K39/12 ,  C12N5/0043 ,  C12N7/00 ,  C12N2500/25 ,  C12N2500/40 ,  C12N2501/02 ,  C12N2501/11 ,  C12N2501/39 ,  C12N2501/395 ,  C12N2720/12334 ,  C12N2720/12351

Abstract: Defined serum-free, low protein media (LPKM), that supports 1) Vero cell growth for up to 20 passages, 2) Vero cell growth on microcarriers and 3) rotavirus production is provided. Maximum cell densities attained are 60-100% of that in serum-containing medium; the doubling time is equal to that for cells in serum containing medium. Rotavirus titers achieved in LPKM-1 are 50-100% of the serum-containing process. Finally, since LPKM-1 contains no animal-sourced proteins, the problems associated with the serum-containing rotavirus production process (i.e. lengthy wash steps before infection, potential introduction of adventitious agents and lot-to-lot variability) can be avoided; while maintaining nearly equivalent product titers.

Abstract translation: 定义无血清，低蛋白质培养基（LPKM），其支持1）Vero细胞生长多达20代，2）提供微载体上的Vero细胞生长和3）轮状病毒生产。 获得的最大细胞密度为含血清培养基的最大细胞密度的60-100％; 倍增时间与含血清培养基中的细胞相同。 在LPKM-1中实现的轮状病毒滴度为含血清过程的50-100％。 最后，由于LPKM-1不含动物来源的蛋白质，因此可以避免与血清轮状病毒生产过程相关的问题（即感染前长时间的洗涤步骤，潜在的引入外来物质和批次间变异性）。 同时保持几乎相当的产品滴度。

公开(公告)号：US06544731B1

公开(公告)日：2003-04-08

申请号：US09197221

申请日：1998-11-20

Applicant: Andrew David Griffiths ,  Hendricus Renerus Jacobus Mattheus Hoogenboom ,  James David Marks ,  John McCafferty ,  Gregory Paul Winter ,  Geoffrey Walter Grigg

Inventor： Andrew David Griffiths ,  Hendricus Renerus Jacobus Mattheus Hoogenboom ,  James David Marks ,  John McCafferty ,  Gregory Paul Winter ,  Geoffrey Walter Grigg

IPC: C12N700

CPC classification number: C40B40/02 ,  B01J2219/00718 ,  C07K16/005 ,  C07K16/18 ,  C07K16/22 ,  C07K16/241 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2812 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/3007 ,  C07K16/3092 ,  C07K16/34 ,  C07K16/40 ,  C07K16/4208 ,  C07K16/4241 ,  C07K16/44 ,  C07K16/462 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/41 ,  C07K2319/735 ,  C12N15/1037 ,  C12N15/62 ,  Y10S530/867

Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal. Synthetic or artificial libraries are described and shown to be useful.

Abstract translation: 公开了用于产生抗自身抗体和抗体片段的方法，其是结合该物种的自身抗原的特定哺乳动物种类的抗体或片段。 方法包括提供可复制的遗传显示包（rgdps）文库，例如丝状噬菌体，每个rgdp在其表面上显示作为抗体或抗体片段的特异性结合对的成员，以及每个含rgdp的核酸序列衍生自 哺乳动物的种类 每个rgdp中的核酸序列编码多肽链，其是在该rgdp的表面显示的sbp成员的组成部分。 通过与来自所述哺乳动物种的自身抗原结合来选择抗自身抗体片段。 显示的抗体片段可以是scFv，Fd，Fab或具有结合抗原能力的任何其它片段。 所使用的核酸文库可以来源于未免疫的哺乳动物的重新排列的V基因序列。 描述和显示合成或人造文库是有用的。

公开(公告)号：US06495361B1

公开(公告)日：2002-12-17

申请号：US09621579

申请日：2000-07-21

Applicant: Paul L. Hermonat ,  Yong Liu

Inventor： Paul L. Hermonat ,  Yong Liu

IPC: C12N700

CPC classification number: C12Q1/708 ,  A61K39/00 ,  C12N7/00 ,  C12N2710/20051 ,  G01N2333/025

Abstract: The present invention is discloses an improved method of producing infectious papillomavirus in vitro, with a method comprising (a) introducing papillomavirus or papillomavirus DNA or portions thereof necessary for replication, into an epithelial cell; and (b) providing conditions that produce papillomavirus, wherein the conditions comprise not contacting the epithelial cell a fibroblast and does not comprise an organotypic raft culture or a dermal equivalent. The present invention also discloses a papillomavirus infected non-keratinocyte epithelial cell produced by the methods of the present invention. Further, uses of the disclosed method includes detection methods, methods for screening anti-papillomavirus drugs, methods of making recombinant papillomavirus for vaccines and studying the life cycle. Additionally, a method of reducing and assessing the risk of spontaneous abortion is disclosed.

Abstract translation: 本发明公开了一种在体外产生感染性乳头瘤病毒的改进方法，其方法包括（a）将乳头状瘤病毒或乳头瘤病毒DNA或其复制所必需的部分引入上皮细胞; 和（b）提供产生乳头瘤病毒的条件，其中所述条件不包括使上皮细胞与成纤维细胞接触，并且不包括器官型筏培养物或皮肤等效物。 本发明还公开了通过本发明的方法生产的乳头瘤病毒感染的非角化细胞上皮细胞。 此外，所公开的方法的用途包括检测方法，用于筛选抗乳头状瘤病毒药物的方法，制备用于疫苗的重组乳头瘤病毒的方法和研究生命周期。 另外，公开了减少和评估自然流产风险的方法。

公开(公告)号：US06482632B1

公开(公告)日：2002-11-19

申请号：US09295851

申请日：1999-04-21

Applicant: Pushpa Agrawal ,  Vishal Soni

Inventor： Pushpa Agrawal ,  Vishal Soni

IPC: C12N700

CPC classification number: C12N7/00 ,  C12N1/20 ,  C12N2770/00051 ,  C12N2795/10021 ,  C12N2795/10051

Abstract: The present invention provides a isolated bacteriophage useful as a tool for studying biological, biochemical, physiological and genetic properties of actinomycetes and other organisms which comprises a novel strain of Saccharomonospora having certain specified characteristics. The invention also relates to a process for the isolation of the said bacteriophage and/or DNA phage and to a novel universal growth medium which is particularly useful in the said process. Another embodiment of the process relates to a cloning vector which comprises a plasmid or bacteriophage comprising the phage DNA of the invention.

Abstract translation: 本发明提供了一种分离的噬菌体，其用作研究放线菌和其它生物体的生物学，生物化学，生理学和遗传学性质的工具，其包含具有某些特定特征的新型Saccharomonospora菌株。 本发明还涉及用于分离所述噬菌体和/或DNA噬菌体的方法以及在所述方法中特别有用的新型通用生长培养基。 该方法的另一个实施方案涉及包含包含本发明的噬菌体DNA的质粒或噬菌体的克隆载体。

公开(公告)号：US06458578B1

公开(公告)日：2002-10-01

申请号：US09748044

申请日：2000-12-22

Applicant: Douglas E. Brough ,  Imre Kovesdi

Inventor： Douglas E. Brough ,  Imre Kovesdi

IPC: C12N700

CPC classification number: C12N15/86 ,  A61K48/00 ,  C12N2710/10343

Abstract: The present invention provides a recombinant cell line, specifically one that produces adenoviral E1 and DEF-A and/or DEF-B gene products.

Abstract translation: 本发明提供重组细胞系，特别是产生腺病毒E1和DEF-A和/或DEF-B基因产物的细胞系。

公开(公告)号：US06410300B1

公开(公告)日：2002-06-25

申请号：US09228203

申请日：1999-01-11

Applicant: Richard Jude Samulski ,  Candace Summerford

Inventor： Richard Jude Samulski ,  Candace Summerford

IPC: C12N700

CPC classification number: C12N15/86 ,  A61K48/00 ,  C12N7/00 ,  C12N2750/14143 ,  C12N2750/14151

Abstract: Primary receptors and co-receptors for adeno-associated virus (AAV) attachment to and infection of target cells are described. Such receptors can be used to facilitate AAV attachment to and infection of cells, e.g., for gene therapy. Methods for purification and/or concentration of AAV are also described. Methods of facilitating or enhancing AAV infection of a cell are also provided. Also described are methods of inhibiting or preventing infection of AAV into a cell. Cell samples may be screened for permissiveness for AAV attachment and infection by detecting the presence or abundance of cellular receptors that mediate attachment and/or infection of AAV into the cell. Formulations and kits for mediating AAV attachment to, and infection of, cells are also provided herein.

公开(公告)号：US06291226B1

公开(公告)日：2001-09-18

申请号：US09258209

申请日：1999-02-25

Applicant: Bernard Massie ,  Wahiba Oualikene

Inventor： Bernard Massie ,  Wahiba Oualikene

IPC: C12N700

CPC classification number: C12N7/00 ,  A61K39/00 ,  A61K48/00 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2710/10352 ,  C12N2810/50 ,  C12N2830/003 ,  C12N2840/20 ,  C12N2840/203

Abstract: An adenovirus vector/packaging cell line system is disclosed, in which the vector replication is blocked by deletion of a single gene, which deletion does not interfere with any other viral functions. The deleted gene is the gene of the adenovirus protease. The protease is expressed in a complementing (packaging) cell line through a regulatable expression cassette which induces no toxic effects in the cells, thus making the generation and propagation of the vector easier and more efficient. As the deleted gene is highly specific of adenovirus, no complementation of the gene in transduced cells is expected, which increases the safety of the new vectors for gene transfer purposes. Also disclosed is a new system of generating recombinant adenovirus vectors by positive selection of recombinants deleted for the endogenous protease gene, which gene is cloned in another region of the adenoviral genome.

Abstract translation: 公开了腺病毒载体/包装细胞系系统，其中通过缺失单个基因阻止载体复制，该缺失不干扰任何其它病毒功能。 删除的基因是腺病毒蛋白酶的基因。 蛋白酶通过可调节表达盒在补体（包装）细胞系中表达，其在细胞中不产生毒性作用，因此使得载体的产生和繁殖更容易和更有效。 由于缺失的基因是腺病毒的高度特异性，所以预期在转导的细胞中不能互补基因，这增加了用于基因转移目的的新载体的安全性。 还公开了通过阳性选择为内源性蛋白酶基因缺失的重组体产生重组腺病毒载体的新系统，该基因被克隆在腺病毒基因组的另一区域中。

公开(公告)号：US06204044B1

公开(公告)日：2001-03-20

申请号：US08465747

申请日：1995-06-06

Applicant: Caroline Sarah Brown

Inventor： Caroline Sarah Brown

IPC: C12N700

CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N7/00 ,  C12N2710/14143 ,  C12N2750/14123 ,  C12N2750/14222

Abstract: The invention relates to the coat proteins VP1 and VP2 of the human parvovirus B19 and virus-like particles consisting of VP2 or of VP1 and VP2. The invention further comprises genetic information in the form of recombinant expression vectors which contain the genes coding for said proteins, and organisms which through genetic manipulation using such vectors have acquired the ability to produce such proteins and/or particles. The invention further comprises uses of such proteins and virus-like particles for diagnostics or vaccination.

Abstract translation: 本发明涉及人细小病毒B19的外壳蛋白VP1和VP2以及由VP2或VP1和VP2构成的病毒样颗粒。 本发明进一步包含含有编码所述蛋白质的基因的重组表达载体形式的遗传信息，并且通过使用这种载体的遗传操作获得了产生这种蛋白质和/或颗粒的能力的生物体。 本发明进一步包括这些蛋白质和病毒样颗粒用于诊断或接种疫苗的用途。